Bioanalysis Zone

Mass spectrometry based metabolomics: a novel analytical technique for detecting metabolic syndrome?


Metabolic syndrome: a global health concern

The rapid growth in obesity prevalence is causing an epidemic of health consequences leading to an astounding socioeconomic burden in the USA and abroad [1]. A recent commission focused on predicting the prevalence and medical costs of cardiovascular disease (CVD) estimated that by 2035, 45% of the US population will have some form of CVD [2]. In 2016 alone, CVD cost Americans 555 billion dollars and by 2035 that cost is estimated to reach 1.1 trillion [2]. Metabolic syndrome (MetS) is defined as the presence of more than three cardiometabolic risk factors, which include central obesity, hypertension, elevated fasting glucose and dyslipidemia [3]. MetS increases the risk for both CVD [3] and diabetes [4]. In the USA, MetS affects up to 30–40% of the general population by age

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Find out more about Jiangjiang (Chris) Zhu and his research in our interview series: ‘An author’s perspective‘.


Leave A Comment